纵横研报
Ticker Detail

603229.SHG

¥8.56+2.27% 奥翔药业 Biotechnology
00Reports China 医疗健康
Zhejiang Ausun Pharmaceutical Co Ltd
医疗健康 · 生物科技

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is based in Linhai, China.

MARKET 市值 6.72B CNY PE 57.8x 52W ¥7.53 – ¥12.51 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY 0.7% ROE 4.6% 营业利润率 41.3% 净利润率 13.6%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制